Radiopharmaceuticals, integrated into modern oncology, offer innovative therapeutic and diagnostic approaches. Radiopharmaceuticals—a combination of targeted therapy with DNA damaging radiation therapy—have the potential to shape future treatment regimens in oncology. Historically, complex radiopharmaceuticals have been difficult to manufacture, distribute, and administer to patients; however, recent advances are focused on alleviating these challenges.
In this article, we will discuss the radiopharmaceutical trial landscape, unveiling a detailed pipeline spanning varied phases, targeting mechanisms, and isotopes utilizing real-world analytics from Citeline. We conclude by spotlighting Precision for Medicine’s past and present achievements in the field of radiopharmaceuticals.
Understanding the landscape of Radiopharmaceutical trials
The field of radiopharmaceuticals is evolving rapidly with the dual aim of improving diagnostics and offering targeted therapeutic solutions. The focus remains on increasing precision, ensuring safety, and personalizing treatment plans to enhance patient outcomes.
- Increased precision and personalization: Newer radiopharmaceuticals are being developed to target specific molecular markers, making them more precise and reducing radiation exposure to healthy tissues.
- Moving beyond cancer: While cancer remains a major focus, radiopharmaceuticals are being studied in other diseases such as Alzheimer’s, Parkinson’s and cardiovascular diseases.
- New radioisotopes: Expanding the number of available radioisotopes with different properties will allow for targeting diverse diseases and improved efficacy.
- Safety and regulatory emphasis: As with all pharmaceuticals, there's a continuous focus on safety. For radiopharmaceuticals safety focuses not just on the patient, but also healthcare providers and the environment. The regulatory environment is adapting to ensure the safe production, administration, and disposal of these agents.
Radiopharmaceutical clinical trials by status
Trial status is one way to examine the current interest in radiopharmaceuticals. Using Citeline’s Trialtrove, we can see that 1,460 radiopharmaceutical trials are on record and almost 28% of them are planned or ongoing.
Radiopharmaceutical Clinical Trials by Status
Citeline, Trialtrove, Accessed 9 February 2024
Planned & ongoing Radiopharmaceutical study starts by year
Radiopharmaceutical trials are an increasing focus in new research, as evidenced by these study starts.
Planned & Ongoing Radiopharmaceutical Trials by Start Date
Citeline, Trial Trove, Accessed 9 February 2024
Emerging hotspots in Radiopharmaceutical research
The United States is emerging as a hotspot for radiopharmaceutical research. Most of these trials are taking place in the US; with China, Australia, France, and Canada rounding out the top five.
Planned & Ongoing Radiopharmaceutical Trials by Site Country
Citeline, Trial Trove, Accessed 9 February 2024
Planned & ongoing Radiopharmaceutical trials by phase
Each phase of a radiopharmaceutical clinical trial has a purpose in deducing drug safety, efficacy, and dosage. These data pinpoint a significant number of trials in early development with over 80% of trials in Phase 1, Phase 1-2, or Phase 2.
Planned & Ongoing Radiopharmaceutical Trials by Phase
Citeline, Trial Trove, Accessed 9 February 2024
Precision’s experience in Radiopharmaceuticals
Radiopharmaceuticals, integrated into modern oncology, offer innovative therapeutic and diagnostic approaches. With the rise in new cancer diagnoses every year, the potential for radiopharmaceuticals to shape future treatment regimens is immense. Precision for Medicine is committed to supporting these trials. As a global clinical research organization, our focus is on advancing radiopharmaceutical research.
Precision Radiopharmaceutical trial starts by year
In the past five years, Precision for Medicine has initiated six radiopharmaceutical trials. The accompanying graphic provides a detailed overview of our trials.
Precision for Medicine’s Radiopharmaceutical Trials by Start Date
Citeline, Trial Trove, Accessed 18 January 2024
Mapping Precision’s Radiopharmaceutical geographic reach
Our work in radiopharmaceutical research extends globally. While our roots are in the United States, we’ve conducted trials in several countries and regions, including Canada, Australia, and Europe. The graphic below illustrates our global reach in radiopharmaceuticals.
Precision for Medicine’s Radiopharmaceutical Trials by Site Country
Citeline, Trial Trove, Accessed 18 January 2024
Precision’s experience in Radiopharmaceutical trials
Our radiopharmaceutical clinical trials span multiple indications in oncology. The following graphic breaks down our experience by indication.
Precision for Medicine’s Radiopharmaceutical Trials by Indication
Citeline, Trial Trove, Accessed 18 January 2024
Precision’s radiopharmaceutical trials by phase
We have broad experience across different trial phases ranging from Phase 1 to larger Phase 2 and Phase 3 trials. The accompanying graphic provides a comprehensive view of our trials by phase.
Precision for Medicine’s Radiopharmaceutical Trials by Indication
Citeline, Trial Trove, Accessed 18 January 2024
Precision for Medicine's commitment to advancement
Our work in this domain is more than just an exploration—it's a reflection of our deep-rooted commitment to redefine medical boundaries. By understanding the broad spectrum of radionuclides and leading the way in theranostic approaches, Precision is on a mission to maximize the potential of radiopharmaceuticals, one clinical trial at a time.
Take a deeper dive into our expertise working with radiopharmaceuticals.
